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A B S T R A C T
Purpose: We conducted a prospective, multicenter, open label trial to evaluate the effectiveness of
oxcarbazepine (OXC) oral suspension as monotherapy for children newly diagnosed with partial seizures.
Methods: This trial included a two- to eight-week titration and stabilization period to achieve effective
target doses and a 24-week maintenance phase. The primary outcome measure was the seizure-free rate
over six months, while a secondary measure was the change in cognition and behavior from screening to
the end of the maintenance phase. The effectiveness of OXC was compared in intellectually normal versus
intellectually impaired children (intelligence quotient <70).
Results: We enrolled 171 patients and analyzed 168 as the per-protocol (PP) group (3 patients had
protocol violations). The mean age of the PP group was 8.4  2.7 years. The maintenance dose of OXC was
24.9  8.0 mg/kg/day. Of the 168 patients included in the efﬁcacy analysis, 122 (72.6%) completed the study
and 94 (56.0%) became seizure-free after the OXC treatment. Comparing the efﬁcacy of OXC for intellectually
normal and intellectually impaired patients, 79 (56.8%) of the 139 intellectually normal patients and 15
(51.7%) of the 29 intellectually impaired patients became seizure-free (P = 0.61). After treatment, intelligence
scale scores improved in intellectually normal patients compared to the intellectually impaired children
(P < 0.05). Social problems quantiﬁed by behavior scales improved in intellectually impaired patients
compared to intellectually normal children (P < 0.05).
Conclusions: OXC is effective and well-tolerated as monotherapy in children with partial seizures. There
was no difference in the effectiveness of OXC between intellectually normal and intellectually impaired
children.
 2012 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
Contents lists available at SciVerse ScienceDirect
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Oxcarbazepine (OXC) is an antiepileptic drug (AED) that is
chemically related to carbamazepine and is approved for the initial
or add-on treatment of partial seizures.1 OXC is also one of the
ﬁrst-line AEDs used for the treatment of partial seizures in* Corresponding author at: Department of Pediatrics, Korea University Guro
Hospital, #97, Gurodong-gil, Guro-gu, Seoul 152-703, Republic of Korea.
Tel.: +82 2 2626 3153; fax: +82 2 2626 1249.
E-mail address: bleun@korea.ac.kr (B.-L. Eun).
1059-1311/$ – see front matter  2012 British Epilepsy Association. Published by Else
http://dx.doi.org/10.1016/j.seizure.2012.07.007children. However, only a few studies have prospectively
evaluated OXC as a primary monotherapy in children with newly
diagnosed epilepsy. Both cognitive and behavioral effects are key
considerations in the selection of AEDs because of the inﬂuence of
these parameters on the acquisition of new skills and the ability to
develop social strategies at crucial stages of development. In this
study, we evaluated the efﬁcacy and tolerability of OXC as
monotherapy for seizure control, including an analysis of
neuropsychological effects, in children less than 16 years of age
with newly diagnosed epilepsy. We also compared the effective-
ness of OXC in intellectually normal children and intellectually
impaired children.vier Ltd. All rights reserved.
Fig. 1. (A) Trial design; (B) trial progression.
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2.1. Subjects
Children less than 16 years of age were eligible for the study if
they had been diagnosed with epilepsy and had experienced two or
more unprovoked partial seizures within the previous six months.
Exclusion criteria included evidence of a progressive cerebral
lesion or a neurodegenerative metabolic disorder as well as a
history of psychiatric disorder. Patients previously treated with
AEDs were also excluded. Epilepsy was classiﬁed as symptomatic,
cryptogenic, or idiopathic, in the following manner: symptomatic
epilepsy was diagnosed if a structural brain disorder was identiﬁed
based on abnormal results of the magnetic resonance imaging
(MRI) scan; cryptogenic epilepsy was diagnosed if recurrent partial
seizures were present despite normal MRI scan results; and a
diagnosis of idiopathic epilepsy was made when no underlying
structural brain or metabolic abnormality could be identiﬁed
based on normal results of the diagnostic tests, and a genetic
predisposition was suspected (i.e. benign rolandic epilepsy and
benign occipital epilepsy).
The study was conducted at ten referral hospitals for pediatric
epilepsy care and its protocol was approved by the institutional
review boards of all of the participating centers. Informed consent
was obtained from all participants as well as their guardians before
any trial-related procedures were performed.
2.2. Study design
The study was an open-labeled, multicenter clinical trial for
OXC monotherapy in children with partial seizures. The study
included a retrospective baseline phase of six months and a
screening phase of one week during which eligibility was
determined and all screening procedures were carried out. The
26- to 32-week treatment periods included an initial titration and
stabilization phase of 2–8 weeks and a maintenance period of 24
weeks. Before starting medication, all subjects were evaluated for
their intelligence, behavior, and quality of life at baseline. OXC was
introduced at 5–10 mg/kg daily and increased by 5–10 mg/kg/day
every one to two weeks. The maintenance dose for OXC was 20–
30 mg/kg/day. Blood levels of OXC were not measured. If the
seizure frequency or intensity increased compared to that of
baseline, the dose was increased gradually up to an effective and
tolerable dose. If, however, maintenance of OXC was rendered
difﬁcult due to adverse effects during titration or within eight
weeks of reaching the maintenance dose, the dose was then
gradually reduced (Fig. 1A).
2.3. Outcome measures
Throughout the trial, patients (or their parents or legal
guardians) maintained diaries to record the types and frequencies
of seizures as well as adverse effects. At each hospital visit, the
investigator reviewed the patient’s seizure diary. Patient visits
were scheduled for visits on day 1 (screening) and then in weeks 4,
8, 12 and 20, and once during weeks 24–28.
The primary efﬁcacy endpoint was the seizure-free rate during
the maintenance period, while secondary efﬁcacy endpoints
included changes in cognition and behavior in a combined analysis
of standardized measures from the screening period to the end of
the maintenance phase. Comprehensive neuropsychological tests
were carried out during the screening period (up to 7 days before
the start of the titration) as well as at the end of the study (28
weeks). The Korean Wechsler Intelligence Scale for Children-Third
Edition (K-WISC-III) was used for cognitive assessment. The K-
WISC-III comprises a full scale intelligence quotient (IQ), verbal IQ,and performance IQ with 13 subtests: information, similarities,
arithmetic, vocabulary, comprehension, digit span, picture com-
pletion, picture arrangement, block design, object assembly,
coding, mazes and symbol search. Verbal IQ is based on
information, similarities, arithmetic, vocabulary and comprehen-
sion. The performance IQ is based on picture completion, coding,
picture arrangement, block design and object assembly. An
integrated cognitive function index was obtained with the results
of the K-WISC-III as follows: (1) verbal comprehension index:
information, similarities, vocabulary and comprehension; (2)
perceptual organization index: picture completion, picture ar-
rangement, block design and object assembly; (3) freedom from
distractibility index: arithmetic and digit span; and (4) processing
speed index: coding and symbol search.
To measure the extent of behavioral problems, the Korean child
behavior checklist (K-CBCL) was used. The K-CBCL is divided into
social competence and behavioral problem analysis, with the
former providing assessments of total social competence, school
and social problems, and the latter providing one score for total
behavioral problems, two second-order factor scores for internal-
izing and externalizing problems, and eight syndrome scales for
assessing aggressive behavior, anxious/depressed, delinquent
behavior, attention problems, social problems, thought problems,
and withdrawn and somatic complaints. The T-scores of these 14
subscales of the K-CBCL were used in the analysis. The Korean
Quality of Life Survey for Childhood Epilepsy (K-QOLCE) consists of
a 42-item scale that assesses well-being, social activity, physical
activity, cognitive functioning, behavioral functioning, general
health and overall quality of life within the previous four weeks.
The overall quality-of-life scoring scale ranges from 0 to 100, with
higher scores representing better quality of life.
The tolerability and safety of OXC were monitored throughout
the trial by neurological and physical examinations that took into
account patient weight, vital signs and an evaluation of treatment-
related adverse effects (one visit during the baseline period
followed by ﬁve subsequent visits during the 28-week trial).
Clinical laboratory assessments (hematology, blood chemistry, and
S.-H. Eun et al. / Seizure 21 (2012) 679–684 681urinalysis) were also performed at baseline, after four weeks of
treatment, and at the end of the study. The incidence of treatment-
related adverse effects was compared between intellectually
normal and intellectually impaired children.
2.4. Statistical methods
For analysis of the seizure-free rate during the treatment
period, which was the primary efﬁcacy parameter of interest, the
intention-to-treat (ITT) population included all patients who
enrolled in this study and received at least one dose of OXC. The
per-protocol (PP) population for efﬁcacy analyses included all ITT
patients who received at least one dose of OXC and provided at
least one on-treatment efﬁcacy evaluation, while patients with at
least one protocol violation were excluded. A chi-squared test was
used to compare seizure outcomes between the intellectually
normal and intellectually impaired children. The data from
neuropsychological tests are summarized as means with standard
deviations (SDs) or as numbers (percentages). A paired Student’s t-
test across the neuropsychological variables was used to compare
changes over time for each treatment group. Mean changes over
time between groups were compared using the Student’s t-test. All
reported P-values were two-tailed and P-values less than 0.05 were
considered statistically signiﬁcant. Statistical analyses were
performed using SPSS software version 19.0 (SPSS Inc., Chicago,
IL, USA).
3. Results
3.1. Subject characteristics and distribution
The ITT population included 171 subjects, consisting of 99 boys
and 72 girls, with a mean age of 8.9  2.7 (range, 3–15) years. After
accounting for the 3 patients with protocol violations, 168 subjects
were analyzed as the PP group, which consisted of 98 boys and 70
girls with a mean age of 8.4  2.7 (range, 3–15) years. Epilepsy was
classiﬁed as symptomatic, cryptogenic, or idiopathic, the latter group
composed of 60 cases of benign rolandic epilepsy and 3 cases of
benign occipital epilepsy. The known causes of symptomatic epilepsy
were encephalomalacia (3 patients, 1.8%), brain atrophy (3, 1.8%),
brain malformation (3, 1.8%), hippocampal sclerosis (3, 1.8%), brain
tumor (1, 0.6%), and stroke (1, 0.6%). The two groups (intellectually
normal and intellectually impaired patients) were similar with regard
to gender and age (Table 1). Of the 139 intellectually normal patients
in the PP population, consisting of 79 boys and 60 girls, there were 63
patients (36 boys, 27 girls) with idiopathic epilepsy and 76 patients
(44 boys, 32 girls) with cryptogenic/symptomatic epilepsy. All 29
intellectually impaired children (19 boys and 10 girls) had
cryptogenic/symptomatic forms of epilepsy. Etiological differences
were apparent between the intellectually normal and intellectually
impaired patient groups (P < 0.001).Table 1






Age (years), mean  SD 8.26  2.55 8.86  3.26 0.728a
Male:female ratio 79:60 19:10 1.0b
Epilepsy classiﬁcation and etiology, n (%) <0.001b
Idiopathic 63 (45.3%)
Cryptogenic 70 (50.4%) 20 (69.0%)
Symptomatic 6 (4.3%) 9 (31.0%)
a Student’s t-test.
b Fisher’s exact test.Fig. 1A and B describes the study design and the distribution,
respectively, of subjects following enrollment. Among the 168 PP
patients, 46 patients (27.4%) did not complete the study due to
drug ineffectiveness (13 patients, 7.7%), loss to follow-up (17,
10.1%), or adverse effects (16, 9.5%). Among the 13 patients who
experienced drug ineffectiveness, two had idiopathic epilepsy and
11 had cryptogenic/symptomatic forms of epilepsy. Adverse
effects that resulted in drug discontinuation were all associated
with skin rashes that occurred after OXC treatment was started.
3.2. Efﬁcacy analysis for seizure-free rate during six months of
maintenance
Seventy-nine patients (56.8%) in the intellectually normal
group and 15 (51.7%) in the intellectually impaired group fulﬁlled
the primary objective of six months of freedom from seizures
(P = 0.614). Table 2 shows the seizure-free rate according to
etiology for the 24 weeks of the maintenance period. Among the 63
patients with idiopathic epilepsy, 42 patients (66.7%) became
seizure-free, while 44 (48.9%) of 90 patients with cryptogenic
epilepsy and 8 (53.3%) of 15 patients with symptomatic epilepsy
became seizure-free. Overall, seizure-free rates during the
maintenance period were not different between groups according
to etiology (P = 0.614 for all partial epilepsy; P = 0.535 for
cryptogenic epilepsy; P = 0.608 for symptomatic epilepsy).
3.3. Neuropsychological assessments
3.3.1. Cognition
Results of the comparison of baseline-to-endpoint changes
between the intellectually normal and intellectually impaired
groups are summarized in Tables 3 and 4. Neuropsychological data
for cognitive variables were available for 113 patients (97 in the
intellectually normal and 16 in the intellectually impaired group).
After treatment, the perceptual organization, attention and
concentration, and picture completion subtests were improved
in the intellectually normal group (P < 0.05). A comparison of the
intellectually normal and impaired groups showed that results for
the information subtest in the intellectually impaired group were
signiﬁcantly worse than that in the intellectually normal group
(P = 0.008) (Table 3).
3.3.2. Behavior
Neuropsychological data for behavioral variables were provid-
ed by 108 patients (93 in the intellectually normal group and 15 in
the intellectually impaired group). In the intellectually normal
group, depression/anxiety (P = 0.010), thought problems
(P = 0.034), delinquent behavior (P = 0.016), and overall behavioral
problems (P = 0.035) were improved after treatment, while in the
intellectually impaired group, somatic complaints (P = 0.021),
depression/anxiety (P = 0.013), social problems (P = 0.022), inter-
nalizing problems (P = 0.007), and overall behavioral problems
(P = 0.025) were improved after treatment. A comparison of the
intellectually normal and impaired groups showed that the statusTable 2









Partial epilepsy 79/139 (56.8%) 15/29 (51.7%) 0.614a
Idiopathic 42/63 (66.7%) – –
Cryptogenic 33/70 (47.1%) 11/20 (55.0%) 0.535a
Symptomatic 4/6 (66.7%) 4/9 (44.4%) 0.608b
a Chi-squared test.
b Fisher’s exact test.
Table 3
Cognition changes after OXC treatment in the per-protocol population.
Intelligence (K-WISC-III) Intellectually normal (n = 97) Intellectually impaired (n = 16) Intellectually normal
vs. impaired







Full scale IQ 97.68 (15.68) 1.268 (9.90)" 0.210 44.88 (12.48) 0.250 (4.98)" 0.844 0.577
Verbal IQ 98.57 (15.04) 0.622 (9.14)" 0.502 52.47 (14.28) 0.733 (5.93)# 0.640 0.407
Performance IQ 97.06 (15.66) 2.268 (13.24)" 0.095 47.19 (13.17) 0.375 (5.22)" 0.778 0.508
Verbal comprehension 98.57 (15.16) 1.012 (9.00)" 0.312 51.64 (13.51) 0.143 (6.79)" 0.938 0.769
Perceptual organization 96.53 (14.82) 3.506 (11.61)" 0.008 47.86 (12.94) 0.786 (3.01)" 0.348 0.390
Attention and concentration 95.74 (16.23) 2.695 (11.98)" 0.045 53.43 (16.36) 0.000 (8.86) 1.000 0.291
Processing speed 99.30 (14.48) 0.463 (14.83)" 0.781 60.14 (12.82) 0.853 (5.85)# 0.593 0.310
Information 9.98 (3.18) 0.020 (1.96)" 0.918 3.06 (2.01) 0.438 (1.45)# 0.249 0.008
Similarities 10.70 (3.12) 0.398 (2.31)" 0.091 3.75 (2.40) 0.313 (2.27)" 0.590 0.085
Arithmetic 9.58 (2.91) 0.061 (2.46)" 0.806 2.69 (2.44) 0.250 (1.23)# 0.432 0.556
Vocabulary 9.93 (2.99) 0.000 (2.54) 1.000 3.00 (2.55) 0.188 (2.07)" 0.723 0.095
Comprehension 9.34 (2.61) 0.255 (2.78)# 0.367 2.69 (2.52) 0.375 (1.36)# 0.287 0.883
Digit span 9.37 (3.01) 0.402 (2.06)" 0.081 2.71 (2.61) 0.286 (1.93)" 0.591 0.627
Picture completion 9.33 (2.64). 0.567 (2.70)" 0.042 2.88 (2.15) 0.313 (1.07)" 0.264 0.770
Picture arrangement 9.48 (2.67) 0.704 (3.22)" 0.053 2.50 (1.78) 0.071 (1.54)" 0.865 0.637
Block design 9.93 (3.02) 0.031 (2.25)# 0.893 2.56 (1.78) 0.125 (1.08)# 0.652 0.272
Picture assembly 9.46 (2.69) 0.351 (2.89)" 0.236 3.44 (2.36) 0.25 (1.91)# 0.609 0.430
Coding 9.46 (2.62) 0.333 (2.98)" 0.318 2.64 (1.73) 0.071 (1.85)" 0.888 0.466
" and # indicate a trend toward improvement or deterioration, respectively. OXC, oxcarbazepine; K-WISC-III, Korean Wechsler Intelligence Scale for Children-Third Edition;
IQ, intelligence quotient.
a Paired Student’s t-tests for changes from baseline.
b Student’s t-test for comparing changes from baseline between the intellectually normal and intellectually impaired groups.
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group than in the intellectually normal group (P = 0.011) (Table 4).
3.3.3. Quality of life
Neuropsychological data concerning quality of life were
obtained from 97 patients (83 in the intellectually normal group
and 14 in the intellectually impaired group). In the intellectually
normal group, memory was improved after treatment (P = 0.029),
but there were no signiﬁcant differences in memory improvement
between the two groups (P = 0.493). Overall, the change in quality
of life did not vary signiﬁcantly between the groups (Table 5).
3.4. Adverse effects
There were several drug-related adverse effects (Table 6), but
rash was the only reason that led to withdrawal from the study
during the titration and maintenance period. Rashes developed 6–
30 days after the start of OXC medication in 30 patients (17.9%). Of
these, rashes in 28 patients (16.7%) were assessed as probablyTable 4
Behavioral changes after OXC treatment in the per-protocol population.
Behavior (K-CBCL) Intellectually normal (n = 93) 
Baseline (SD) Change from
baseline (SD)
P-valuea
Social competence 51.99 (13.53) 2.65 (13.65)" 0.066 
School competence 46.34 (19.76) 3.09 (18.33)" 0.108 
Total social competence 46.53 (19.52) 3.26 (18.49)" 0.094 
Withdrawn 50.38 (12.37) 2.16 (15.00)" 0.168 
Somatic complaints 51.65 (8.17) 1.12 (8.82)" 0.225 
Depression/anxiety 49.17 (8.75) 2.22 (8.14)" 0.010 
Social problems 48.68 (8.39) 0.28 (8.94)# 0.762 
Thought problems 49.95 (6.56) 1.61 (7.17)" 0.034 
Attention problems 48.44 (8.99) 0.871 (8.89)" 0.347 
Delinquent behavior 48.35 (7.04) 1.53 (6.01)" 0.016 
Aggressive behavior 47.18 (8.43) 1.25 (7.75)" 0.124 
Internalizing problems 49.59 (8.32) 1.63 (8.44)" 0.065 
Externalizing problems 47.31 (8.15) 1.47 (7.19)" 0.051 
Overall behavioral problems 47.84 (8.17) 1.74 (7.85)" 0.035 
" and # indicate a trend toward improvement or deterioration, respectively. OXC, oxca
a Paired Student’s t-tests for changes from baseline.
b Student’s t-test for comparing changes from baseline between the intellectually norelated to OXC use, while the underlying cause was viral illnesses
in the other 2 patients. OXC-related rashes with mild diffuse
erythematous maculopapules or bullous eruptions with/without
itching presented mainly on the trunk and face. There was
associated fever in 2 patients, but no evidence was seen of Stevens–
Johnsons syndrome (SJS) or toxic epidermal necrolysis. The
starting daily dose of OXC was 9.0  4.6 mg in patients with rashes
and 9.5  4.6 mg in patients without (P = 0.686). OXC was increased
once per week such that the overall daily dose was raised by 5–10 mg/
kg. Fifteen patients (10.8%) in the intellectually normal group and one
patient (3.4%) in the intellectually impaired group withdrew from the
study due to the appearance of a rash (P = 0.311). There were no
serious adverse effects reported during the study period.
4. Discussion
The purpose of this study was to evaluate the efﬁcacy of OXC
monotherapy for seizure control and tolerability in children. The







40.40 (13.66) 1.00 (12.29)" 0.757 0.666
34.20 (11.00) 2.27 (11.54)" 0.460 0.574
32.33 (13.87) 3.20 (11.39)" 0.295 0.272
55.07 (6.45) 2.80 (8.03)" 0.198 0.595
50.80 (7.68) 3.93 (5.89)" 0.021 0.174
51.80 (5.91) 4.93 (6.69)" 0.013 0.128
66.93 (8.53) 7.93 (11.95)" 0.022 0.011
53.80 (10.20) 4.53 (9.57)" 0.088 0.250
59.27 (7.70) 5.40 (9.93)" 0.054 0.086
49.67 (6.26) 1.73 (10.45)" 0.531 0.925
50.67 (8.31) 2.40 (6.31)" 0.163 0.587
52.80 (6.00) 4.60 (5.64)" 0.007 0.135
50.20 (7.74) 2.07 (7.12)" 0.280 0.799
55.87 (5.33) 5.67 (8.73)" 0.025 0.114
rbazepine; K-CBCL, Korean Child Behavior Checklist.
rmal and intellectually impaired groups.
Table 5
Changes in quality of life after OXC treatment in the per-protocol population.
K-QOLCE Intellectually normal (n = 83) Intellectually impaired (n = 14) Intellectually normal
vs. impaired
Baseline (SD) Change from
baseline (SD)
P-valuea Baseline (SD) Change from
baseline (SD)
P-valuea P-valueb
Physical function Physical restriction 392.47 (92.95) 21.39 (99.93)# 0.055 275.00 (106.97) 12.50 (85.91)" 0.959 0.972
Energy/fatigue 146.69 (35.52) 1.09 (39.00)" 0.674 117.86 (43.22) 1.79 (34.62)# 0.850 0.543
Well-being (mood) Depression 40.66 (30.92) 1.51 (29.30)" 0.641 55.36 (32.79) 1.79 (18.25)" 0.720 0.838
Anxiety 224.10 (73.01) 6.63 (94.68)# 0.526 187.50 (47.79) 19.64 (85.58)" 0.406 0.397
Control/helplessness 153.31 (56.68) 1.51 (63.72)# 0.830 128.57 (29.18) 12.50 (55.25)" 0.413 0.883
Self-esteem 219.58 (53.11) 1.80 (48.42)# 0.735 160.71 (61.79) 0.00 (50.0) 1.000 0.588
Cognition Concentration 153.01 (51.56) 0.60 (61.60)" 0.929 98.21 (39.79) 1.79 (55.87)# 0.907 0.532
Memory 157.23 (44.94) 12.65 (51.70)" 0.029 132.14 (50.41) 10.71 (47.75)" 0.416 0.493
Language 282.23 (270.54) 22.89 (281.52)" 0.461 141.07 (76.97) 14.29 (53.45)# 0.336 0.206
Other 154.22 (47.47) 3.61 (45.05)# 0.467 82.14 (49.45) 7.13 (3.66)# 0.414 0.644
Social function Social activities 226.81 (62.93) 1.81 (86.93)" 0.850 175.00 (75.96) 14.29 (76.40)# 0.497 0.294
Social interactions 168.07 (49.44) 6.02 (60.06)" 0.363 117.86 (71.68) 16.07 (78.81)" 0.459 0.805
General Behaviors 561.14 (129.57) 22.29 (154.11)# 0.101 475.00 (90.94) 1.79 (66.84)# 0.349 0.862
Health 60.84 (37.89) 0.90 (42.31)# 0.337 48.21 (33.20) 8.93 (33.40)# 0.336 0.347
Quality of life 57.83 (36.40) 4.22 (39.78)# 0.337 51.79 (35.98) 3.57 (46.89)" 0.780 0.484
Total 2998.19 (595.85) 15.06 (655.32) 0.835 2246.43 (429.99) 28.79 (255.98)" 0.702 0.561
" and # indicate a trend toward improvement or deterioration, respectively. OXC, oxcarbazepine; K-QOLCE, Korean Quality of Life Survey for Childhood Epilepsy.
a Paired Student’s t-tests for changes from baseline.
b Student’s t-test for comparing changes from baseline between the intellectually normal and intellectually impaired groups.
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for seizure control was not different between intellectually normal
and intellectually impaired children. Moreover, there was no
difference in treatment efﬁcacy in relation to the etiology of the
childhood partial epilepsy. OXC was also beneﬁcial in several
subsets of cognition and behavior, such as perceptual organization
and depression/anxiety.
Previous studies investigating OXC have mostly addressed its
adequacy as an add-on therapy in intractable epilepsy patients.2–4
Other studies have also focused mainly on retrospective analyses
through chart review,5,6 while more recent reports describe the
study of the effects of OXC monotherapy in small numbers of
children and young adults via prospective observation.7–11 In
contrast, the present study was conducted on 168 patients with
newly diagnosed, untreated pediatric partial epilepsy (less than 16
years of age) to evaluate the seizure-controlling effects of OXC as a
ﬁrst-line therapy and to address its safety and adverse effects,
including its effects on cognitive functions and behavior. Our
results show that OXC can be used effectively without causing
serious systemic adverse effects. The efﬁcacy of OXC for seizureTable 6





Rash 25 (17.9%)a 5 (17.2%)b
Headache 8 (5.8%) 1 (3.4%)
Somnolence 4 (2.9%) 1 (3.4%)
Dizziness 3 (2.2%) 2 (6.9%)
Fatigue 2 (1.4%) 3 (10.3%)
Anxiety 1 (0.7%) 2 (6.9%)
Ataxia 0 1 (3.4%)
Memory loss 1 (0.7%) 1 (1.6%)
Paresthesia 1 (0.7%) 0
Weight gain 2 (1.4%) 0
Weight loss 1 (0.7%) 0
Epigastric pain 1 (0.7%) 0
Hyponatremia 1 (0.7%) 0
a Fifteen patients in the intellectually normal group.
b One patient in the intellectually impaired group withdrew because of adverse
effects.control did not differ between intellectually normal and intellec-
tually impaired children.
The underlying cause of epilepsy is a major determinant of
treatment, prognosis and clinical course. It has been generally
acknowledged that idiopathic epilepsy responds better to AEDs
than does symptomatic epilepsy; however, our results indicate
that there were no differences in OXC efﬁcacy among the various
groups according to the etiology (idiopathic, cryptogenic, and
symptomatic) of the epilepsy.
In relation to cognition, this study showed that perceptual
organization, attention and concentration, and picture completion
subtests were only improved after treatment in the intellectually
normal group. A particularly interesting ﬁnding here was that
although a follow-up evaluation after a six-month interval may
have inﬂuenced these learning effects, the improvements were
only observed in the intellectually normal group. Moreover, the
result of the information subtest in the intellectually impaired
group was signiﬁcantly poorer than that in the intellectually
normal group. This ﬁnding shows that changes in cognition after
AED treatment relate to baseline cognitive ability prior to
treatment. Although a randomized head-to-head comparison is
required to compare the neurobehavioral effects of AEDs, the
results of this study suggest that OXC could be beneﬁcial to treat
children without risking the possible manifestation of problems
associated with language development that are seen after
treatment with topiramate or zonisamide.12–15 An analysis of
behavioral changes after OXC treatment showed that OXC was
beneﬁcial in relation to several aspects of behavior. In particular,
the social problem parameter in intellectually impaired children
improved signiﬁcantly compared with that of intellectually normal
children.
With respect to drug-related adverse effects, the occurrence of
rash was the only cause for drug withdrawal; these rashes
completely resolved after drug discontinuation. The U.S. Food and
Drug Administration recommends screening for the human
leukocyte antigen (HLA)-B*1502 allele in people of Asian ancestry
before initiating carbamazepine therapy and a recently published
paper reporting HLA genotypes in Koreans showed that HLA-
B*1511 and A*3101 were associated with carbamazepine-induced
SJS and hypersensitivity syndrome/severe cutaneous adverse
S.-H. Eun et al. / Seizure 21 (2012) 679–684684reaction, respectively, in the Korean population.16 We did not
analyze HLA genotypes in this study, but the occurrence of rash
was not related to the initiation dose or the rapidity of dosage
escalation employed here. The evaluation of genetic suscepti-
bility using HLA genotyping would no doubt have proven
helpful. There were no other serious problems after OXC
administration, which implies that OXC can be used safely in
children with epilepsy.
Several limitations to this study should be noted. First, the
study design could be improved, as the follow-up period of 6
months is relatively short for the measurement of pragmatic
outcomes. Additionally, the short interval between cognitive
evaluations may have led to learning effects. Future studies
should include a longer follow-up and use more sensitive tools to
determine more speciﬁc changes, if any, in children’s cognition and
overall behavior.
In conclusion, OXC is an effective monotherapy for newly
diagnosed childhood partial epilepsy. Intellectual ability and the
etiology of partial epilepsy are not predictors of OXC responsive-
ness in pediatric patients.
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